Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Spring Sale
Enjoy this offer
* See conditions under "Our services"

Valuation: Swedish Orphan Biovitrum AB

Capitalization 134B 14.69B 12.62B 11.4B 10.92B 19.94B 1,350B 20.57B 53.79B 647B 55.14B 53.97B 2,317B P/E ratio 2025
243x
P/E ratio 2026 * 23.7x
Enterprise value 145B 15.86B 13.62B 12.31B 11.79B 21.53B 1,457B 22.21B 58.06B 698B 59.53B 58.26B 2,501B EV / Sales 2025
4.06x
EV / Sales 2026 * 4.72x
Free-Float
51.66%
Yield 2025 *
-
Yield 2026 * -

Last Transcript: Swedish Orphan Biovitrum AB

1 day-0.82%
1 week-0.36%
Current month-2.68%
1 month-5.73%
3 months+15.56%
6 months+43.58%
Current year+15.62%
1 week 364.6
Extreme 364.6
392.8
1 month 364.6
Extreme 364.6
432.8
Current year 322
Extreme 322
432.8
1 year 241.8
Extreme 241.8
432.8
3 years 197.9
Extreme 197.9
432.8
5 years 127.1
Extreme 127.1
432.8
10 years 89.5
Extreme 89.5
432.8
Manager TitleAgeSince
Chief Executive Officer 61 22/05/2017
Director of Finance/CFO 59 20/07/2018
Chief Tech/Sci/R&D Officer 55 -
Director TitleAgeSince
Director/Board Member 57 01/01/2020
Director/Board Member 70 01/01/2021
Director/Board Member - -
Change 5d. change 1-year change 3-years change Capi.($)
-0.82%-0.36%+36.36%+61.95% 14.69B
-1.22%+0.70%+3.65%+3.35% 79.23B
-4.56%-4.48%+48.39%+220.95% 58.37B
+0.82%+59.20%+59.20%+59.20% 50.28B
-1.37%-0.20%-43.40%-49.66% 49.67B
+0.09%+2.39%+25.01%-26.56% 27.65B
-1.36%+10.34%+52.89%-60.24% 21.71B
-1.11%-2.09%+34.99%+33.34% 19.11B
-1.75%+8.63%+111.81%+115.05% 19.03B
+13.22%+15.17%+136.69%+428.59% 14.41B
Average +0.36%+4.40%+46.56%+78.60% 35.41B
Weighted average by Cap. -0.72%+3.26%+31.27%+60.83%

Financials

2025 2026 *
Net sales 28.43B 3.11B 2.67B 2.41B 2.31B 4.22B 286B 4.35B 11.38B 137B 11.67B 11.42B 490B 30.97B 3.39B 2.91B 2.63B 2.52B 4.6B 311B 4.74B 12.4B 149B 12.71B 12.44B 534B
Net income 633M 69.21M 59.43M 53.72M 51.44M 93.95M 6.36B 96.91M 253M 3.05B 260M 254M 10.91B 5.75B 629M 540M 488M 467M 854M 57.76B 881M 2.3B 27.69B 2.36B 2.31B 99.15B
Net Debt 10.68B 1.17B 1B 907M 868M 1.59B 107B 1.64B 4.28B 51.44B 4.38B 4.29B 184B 11.82B 1.29B 1.11B 1B 961M 1.75B 119B 1.81B 4.73B 56.93B 4.85B 4.75B 204B
Logo Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (publ) is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.
Employees
1,888
Date Price Change Volume
11/03/26 384.80 kr -0.98% 61,791
10/03/26 388.60 kr +3.41% 330,541
09/03/26 375.80 kr -0.21% 405,732
06/03/26 376.60 kr -1.21% 347,634
05/03/26 381.20 kr -1.29% 319,160
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
388.60SEK
Average target price
423.60SEK
Spread / Average Target
+9.01%

Quarterly revenue - Rate of surprise

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW